Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - budesonide dihydrate; formoterol fumarate dihydrate - inhalation powder - 400/12 µg/µg - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; formoterol and budesonide

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - brimica genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Քենիա - անգլերեն - Pharmacy and Poisons Board

bliss gvs pharma limited 102, hyde park, saki vihar road, andheri (east) - - formoterol fumarate dihydrate bp and budesonide bp - pressurised inhalation - formoterol fumarate dihydrate bp equivalent to… - formoterol and budesonide

Քենիա - անգլերեն - Pharmacy and Poisons Board

bliss gvs pharma limited 102, hyde park, saki-vihar road, andheri (east), - formoterol fumarate dihydrate bp and budesonide bp - pressurised inhalation - formoterol fumarate dihydrate bp equivalent to… - formoterol and budesonide

Իսրայել - անգլերեն - Ministry of Health

astrazeneca (israel) ltd - aclidinium as bromide; formoterol fumarate dihydrate - powder for inhalation - formoterol fumarate dihydrate 11.8 mcg; aclidinium as bromide 340 mcg - aclidinium bromide - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd)

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - formoterol fumarate dihydrate 0,006 µg - inhalation powder - 6 µg - formoterol fumarate dihydrate 6 µg - formoterol

Բելգիա - անգլերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - formoterol fumarate dihydrate 0,012 µg - inhalation powder - 12 µg - formoterol fumarate dihydrate 12 µg - formoterol

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - budesonide, quantity: 320 microgram/actuation; formoterol fumarate dihydrate, quantity: 9 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma,bufomix easyhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration).,chronic obstructive pulmonary disease (copd),bufomix easyhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 less than or equal to 50 percent predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. bufomix easyhaler is not indicated for the initiation of bronchodilator therapy in copd.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - budesonide, quantity: 160 microgram/actuation; formoterol fumarate dihydrate, quantity: 4.5 microgram/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - asthma,bufomix easyhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see section 4.2 dose and method of administration).,chronic obstructive pulmonary disease (copd),bufomix easyhaler is indicated for the symptomatic treatment of moderate to severe copd (fev1 less than or equal to 50 percent predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. bufomix easyhaler is not indicated for the initiation of bronchodilator therapy in copd.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - fluticasone propionate, quantity: 40 mg; formoterol fumarate dihydrate, quantity: 1.6 mg - inhalation, pressurised - excipient ingredients: ethanol absolute; sodium cromoglycate; apaflurane - flutiform inhaler is indicated for the regular maintenance treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2-agonist) is appropriate. this includes patients not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonist on an ?as required? basis.